Avan J. Armaghani

Oncology

4101 Jim Walter Blvd
Tampa, FL 33607

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

A Cohort Study of the Effectiveness of Trastuzumab Deruxtecan for Treating Metastatic Progressive HER2-Positive Breast Cancer.

A Cohort Study of the Effectiveness of Trastuzumab Deruxtecan for Treating Metastatic Progressive HER2-Positive Breast Cancer.

Journal: Clinical breast cancer

Published: April 10, 2026

Neoadjuvant therapy with an aromatase inhibitor and durvalumab in postmenopausal patients with hormone receptor-positive breast cancer.

Neoadjuvant therapy with an aromatase inhibitor and durvalumab in postmenopausal patients with hormone receptor-positive breast cancer.

Journal: Breast cancer research and treatment

Published: July 07, 2025

A Real-World Single-Center Cohort Study on the Tolerability of Trastuzumab Deruxtecan for HER2+ Metastatic Breast Cancer.

A Real-World Single-Center Cohort Study on the Tolerability of Trastuzumab Deruxtecan for HER2+ Metastatic Breast Cancer.

Journal: Oncology

Published: May 16, 2025

Nivolumab and stereotactic radiosurgery for patients with breast cancer brain metastases: long-term results and biomarker analysis from a non-randomized, open-label, phase Ib study.

Nivolumab and stereotactic radiosurgery for patients with breast cancer brain metastases: long-term results and biomarker analysis from a non-randomized, open-label, phase Ib study.

Journal: Journal for immunotherapy of cancer

Published: March 17, 2025

Phase II trial of brain MRI surveillance in stage IV breast cancer.

Phase II trial of brain MRI surveillance in stage IV breast cancer.

Journal: Neuro-oncology

Published: January 24, 2025

Alteration of the Tumor Microenvironment With Intratumoral Dendritic Cells Before Chemotherapy in ERBB2 Breast Cancer: A Nonrandomized Clinical Trial.

Alteration of the Tumor Microenvironment With Intratumoral Dendritic Cells Before Chemotherapy in ERBB2 Breast Cancer: A Nonrandomized Clinical Trial.

Journal: JAMA oncology

Published: December 05, 2024

A pilot study incorporating HER2-directed dendritic cells into neoadjuvant therapy of early stage HER2+ER- breast cancer.

A pilot study incorporating HER2-directed dendritic cells into neoadjuvant therapy of early stage HER2+ER- breast cancer.

Journal: NPJ breast cancer

Published: June 18, 2024

Author Correction: Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial.

Author Correction: Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial.

Journal: Nature medicine

Published: March 18, 2023

Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial.

Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial.

Journal: Nature medicine

Published: April 30, 2022

Making National Cancer Institute-Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational Study.

Making National Cancer Institute-Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational Study.

Journal: JMIR cancer

Published: September 27, 2021

Nivolumab and Stereotactic Radiosurgery for Patients With Breast Cancer Brain Metastases: A Nonrandomized, Open-Label Phase 1b Study.

Nivolumab and Stereotactic Radiosurgery for Patients With Breast Cancer Brain Metastases: A Nonrandomized, Open-Label Phase 1b Study.

Journal: Advances in radiation oncology

Published: August 09, 2021

Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update.

Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 29, 2021

Showing 1-12 of 19

Last Updated: 09/26/2026